To define triple-class refractory means the patient is refractory to FDA-approved IMiDs (up to Pomalidomide), proteasome inhibitors (bortezomib and carfilzomib), and CD38 naked antibodies (e.g. daratumumab or isatuximab). Refractory is defined as progression or within 60 days of the last dose.  ...

I favor a clinical trial with CART or a bispecific, both of those options appear quite efficacious in TCR MM. The BCMA ADC Belamaf with Pom-Dex from Dr. Trudel looks very interesting, as does the Iberdomide data. For t(11;14) TCR MM who have not been treated with venetoclax, I would favor that thera...